Cannovum AG

  • WKN: A2LQU2
  • ISIN: DE000A2LQU21
  • Land: Deutschland

Nachricht vom 08.09.2021 | 13:44

Cannovum AG expands Supervisory Board and Medical Advisory Board

DGAP-News: Cannovum AG / Key word(s): Personnel
08.09.2021 / 13:44
The issuer is solely responsible for the content of this announcement.

Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has appointed Priv. Doz. Dr. med. habil. Philipp Sewerin to the supervisory board. Dr. Sewerin is a specialist in internal medicine and rheumatology at the university clinic in Düsseldorf. In addition to his clinical activities, he's engaged in research and clinical trials, particularly on inflammatory rheumatic diseases. Dr. Sewerin is dedicated to the well-being of patients and is very involved in association work.

In addition to his position on the Supervisory Board, Dr. Sewerin will support Cannovum in an advisory capacity as a scientific expert and new member of the Medical Advisory Board. The field of internal medicine is a major application area of cannabis-based therapies. In addition to the well-known use of cannabis-based medicines in pain therapy, there is great potential for medical cannabis in the treatment of inflammatory diseases such as rheumatism. Dr. Sewerin will contribute his in-depth knowledge to Cannovum's Medical Education. This is an advanced training program to support healthcare professionals in setting up cannabis-based therapies.

"We are pleased to welcome Dr. Sewerin to the Board of Directors and Medical Advisory Board. His professional expertise in the field of internal medicine is an asset to Cannovum's Medical Education and he will support us in improving the care of medical cannabis patients," says Pia Marten, CEO of Cannovum AG.

Contact:

Linda Rasch, IR & PR, Cannovum AG
Phone +49 30 3982 163 62, ir@cannovum.com


Cannovum AG is the first German listed medical cannabis company. The shares are traded on the Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.

For more information, visit www.cannovum.com



08.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

MS Industrie AG

Original-Research: MS Industrie AG (von Montega AG): Kaufen

29. November 2021